PriceTargets.com logo

Virax Biolabs Group - VRAX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.00
  • Forecasted Upside: 365.84%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.64 As of 12/4/2025 05:00 PM ET
▼ -0.044 (-6.40%)

This chart shows the closing price for VRAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Virax Biolabs Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRAX

Analyst Price Target is $3.00
▲ +365.84% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Virax Biolabs Group in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 365.84% upside from the last price of $0.64.

This chart shows the closing price for VRAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Virax Biolabs Group. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/31/2025HC WainwrightInitiated CoverageBuy$3.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Virax Biolabs Group logo
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $0.64
Low: $0.56
High: $0.65

50 Day Range

MA: $0.55
Low: $0.37
High: $0.69

52 Week Range

Now: $0.64
Low: $0.35
High: $3.20

Volume

5,968,022 shs

Average Volume

14,838,136 shs

Market Capitalization

$2.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Virax Biolabs Group?

The following Wall Street research analysts have issued stock ratings on Virax Biolabs Group in the last twelve months: HC Wainwright, and Weiss Ratings.
View the latest analyst ratings for VRAX.

What is the current price target for Virax Biolabs Group?

0 Wall Street analysts have set twelve-month price targets for Virax Biolabs Group in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 365.8%. HC Wainwright has the highest price target set, predicting VRAX will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Virax Biolabs Group in the next year.
View the latest price targets for VRAX.

What is the current consensus analyst rating for Virax Biolabs Group?

Virax Biolabs Group currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VRAX, but not buy more shares or sell existing shares.
View the latest ratings for VRAX.

What other companies compete with Virax Biolabs Group?

Other companies that are similar to Virax Biolabs Group include Biomerica, Genprex, Alzamend Neuro, ProPhase Labs and Creative Medical Technology. Learn More about companies similar to Virax Biolabs Group.

How do I contact Virax Biolabs Group's investor relations team?

The company's listed phone number is 44-0-20-7788-7414 and its investor relations email address is [email protected]. The official website for Virax Biolabs Group is viraxbiolabs.com. Learn More about contacing Virax Biolabs Group investor relations.